Skip to main content

Table 2 Meta-analyses on outcomes of parenchymal damage and perioperative outcomes after preoperative chemotherapy with and without bevacizumab for CLM

From: Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

Histological analyses

 

Subgroup

SOS

Moderate/Severe SOS

Hepatic fibrosis

Hepatic steatosis

Total

-

0.50 [0.37, 0.67]

0.25 [0.17, 0.38];

0.61 [0.44, 0.86]

0.96 [0.63, 1.45]

p < 0.001; I2 = 0 %

p < 0.001; I2 = 0 %

p =0.004; I2 = 7 %

p = 0.83; I2 = 30 %

No of BEV cycles

≤6

0.50 [0.34, 0.72]

0.21 [0.11, 0.41]

0.60 [0.38, 0.94]

0.94 [0.56, 1.59]

p < 0.001; I2 = 0 %

p < 0.001; I2 = 0 %

p = 0.03; I2 = 0 %

p = 0.82; I2 = 53 %

>6

0.46 [0.21, 1.01]

0.29 [0.10, 0.81]

0.43 [0.19, 1.0]

0.93 [0.34, 2.52]

p = 0.05; I2 = 0 %

p = 0.02; I2 = 0 %a

p = 0.05; I2 = 0 %b

p = 0.89; I2 = 31 %

Time last BEV cycle to surgery

≤8 weeks

0.47 [0.23, 0.95]

0.21 [0.10, 0.47]

-

-

p = 0.04; I2 = 32 %

p < 0.001; I2 = 0 %

  

>8 weeks

0.50 [0.28, 0.86]

0.26 [0.12, 0.56]

0.61 [0.34, 1.09]

0.63 [0.21, 1.84]

p = 0.01; I2 = 0 %

p < 0.001; I2 = 0 %

p = 0.09; I2 = 0 %

p = 0.39; I2 = 45 %

Cytotoxic chemotherapy4

Oxaliplatin high

0.46 [0.21, 1.01]

0.29 [0.10, 0.81]

0.43 [0.19, 1.00]

0.93 [0.34, 2.52]

p = 0.05; I2 = 0 %

p = 0.02; I2 = 0 %a

p = 0.05; I2 = 0 %b

p = 0.89; I2 = 31 %

Oxaliplatin low

0.51 [0.37, 0.69]

0.25 [0.16, 0.38]

0.52 [0.37, 0.75]

0.94 [0.56, 1.59]

p < 0.001; I2 = 0 %

p < 0.001; I2 = 0 %

p < 0.001; I2 = 0 %

p = 0.82; I2 = 53 %

Functional Recovery and Perioperative Outcome

  

Morbidity

Wound complications

Liver failure

Mortality

Total

-

1.10 [0.88, 1.37]

1.81 [1.12, 2.91]

0.61 [0.34, 1.07]

0.60 [0.20, 1.82]

p = 0.39; I2 = 10 %

p = 0.02; I2 = 4 %

p = 0.08; I2 = 6 %

p = 0.37; I2 = 0 %

No of BEV cycles

≤6

0.99 [0.75, 1.30]

1.22 [0.61, 2.42]

0.49 [0.21, 1.14]

0.54 [0.10, 2.93]

p = 0.95; I2 = 0 %

p = 0.58; I2 = 0 %c

p = 0.10; I2 = 0 %

p = 0.47; I2 = 0 %

>6

1.51 [1.08, 2.13]

1.88 [0.89, 3.99]

0.85 [0.36, 2.00]

0.46 [0.09, 2.41]

p = 0.02; I2 = 0 %

p = 0.10; I2 = 0 %

p = 0.71; I2 = 16 %

p = 0.36; I2 = 0 %

Time last BEV cycle to surgery

≤8 weeks

1.06 [0.70, 1.59]

1.59 [0.50, 5.11]

0.50 [0.16, 1.57]

1.16 [0.14, 9.37]

p = 0.80; I2 = 33 %

p = 0.43; I2 = 0 %

p = 0.24; I2 = 0 %

p = 0.89; I2 = 0 %

>8 weeks

1.27 [0.92, 1.74]

1.45 [0.84, 2.50]

0.70 [0.32, 1.51]

0.47 [0.13, 1.71]

p = 0.15; I2 = 0 %

p = 0.19; I2 = 0 %

p = 0.36; I2 = 23 %

p = 0.25; I2 = 0 %

Cytotoxic chemotherapyd

Oxaliplatin high

1.19 [0.87, 1.63]

1.47 [0.87, 2.49]

0.61 [0.28, 1.30]

0.55 [0.14, 2.19]

p = 0.28; I2 = 17 %

p = 0.15; I2 = 0 %

p = 0.20; I2 = 29 %

p = 0.40; I2 = 0 %

Oxaliplatin low

1.01 [0.74, 1.38]

3.19 [0.82, 12.35]

0.50 [0.16, 1.59]

0.70 [0.11, 4.47]

p = 0.95; I2 = 6 %

p = 0.09; I2 = 51 %

p = 0.24; I2 = 0 %

p = 0.71; I2 = 0 %

  1. aResults of sensitivity analyses after exclusion of the study by Aussilhou et al. [20]
  2. bResults of sensitivity analyses after exclusion of the study by Wicherts et al. [33]
  3. cResults of sensitivity analyses after exclusion of the study by Rong et al. [28]
  4. dThe subgroup analysis on the kind of systemic chemotherapy administered was based on the fraction of patients who received oxaliplatin or irinotecan. Studies in the oxaliplatin high group had > 76 % of patients who received oxaliplatin, whereas studies in the oxaliplatin low had ≤ 76 % patients with oxaliplatin. This cut-off was chosen based on the average proportion of patients with oxaliplatin in each study